Acticor Biotech

Éric Cohen - Managing Director and Founder of Agile Capital Markets

About the deal

Paris, France, October 27, 2021– ACTICOR BIOTECH (ISIN: FR0014005OJ5 –ALACT), a clinical stage biopharmaceutical company specialized in the development of drugs for treating cardiovascular emergencies, today announces the success of its Initial Public Offering on the Euronext Growth market in Paris.

• Offering price set at €7.12 per share
• Capital increase of €15.5 million
• Global demand of €15.5 million at the offering price (€13.4 million in the Global Placement and €2.1 million in the Open Price Offer)
• Settlement-delivery scheduled for October 29, 2021 and shares scheduled to begin trading on the Euronext Growth® market in Paris on November 1, 2021
• Funds raised to better treat stroke and reduce disability.

Press release

Date 2021

Sector Biotech

Transaction Size €15.5M

Transaction Type IPO

Localisation France